Neurogene Inc. NGNE

US Biotechnology

$25.68 ▼ -1.23% ($-0.32)

🔥 High Short Interest 🎢 High Beta 📅 Earnings This Week

Open $25.23

Prev Close $26.00

Day Range $24.22 – $26.36

52W Range $15.93 – $43.66

Market Cap $520.30M

Beta 1.76

EPS (TTM) $-3.16

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2014-03-07
Shares Out.	20,010,000
Website	neurogene.com ↗
Phone	13026587581
Employees	131
Revenue	$0
Gross Profit	$0
Net Income	-$34.5M
Free Cash Flow	-$87.7M
Total Assets	$244.4M
Total Liabilities	$27.2M
Equity	$217.1M

About Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Neurogene Inc. is a publicly traded company under the ticker symbol NGNE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.